SAGE Quote, Financials, Valuation and Earnings

Biogen has a net margin of -442.4% compared to Sage Therapeutics's net margin of 9.89%. Sage Therapeutics's return on equity of -64.19% beat Biogen's return on equity of 9.11%.

Sage Therapeutics has a consensus price target of $8.21, signalling upside risk potential of 25.2%. On the other hand Biogen has an analysts' consensus of $172.25 which suggests that it could grow by 45.76%. Given that Biogen has higher upside potential than Sage Therapeutics, analysts believe Biogen is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.205, which suggesting that the stock is 79.546% less volatile than S&P 500. In comparison Biogen has a beta of 0.125, suggesting its less volatile than the S&P 500 by 87.479%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $14.1M, which are smaller than Biogen quarterly revenues of $2.4B. Sage Therapeutics's net income of -$62.2M is lower than Biogen's net income of $240.5M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 8.47x versus 1.76x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -442.4% compared to Sage Therapeutics's net margin of -49.65%. Sage Therapeutics's return on equity of -64.19% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Sage Therapeutics has a consensus price target of $8.21, signalling upside risk potential of 25.2%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that NovaBay Pharmaceuticals has higher upside potential than Sage Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.205, which suggesting that the stock is 79.546% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $14.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Sage Therapeutics's net income of -$62.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 8.47x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -442.4% compared to Sage Therapeutics's net margin of --. Sage Therapeutics's return on equity of -64.19% beat Theriva Biologics's return on equity of --.

Sage Therapeutics has a consensus price target of $8.21, signalling upside risk potential of 25.2%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1032.29%. Given that Theriva Biologics has higher upside potential than Sage Therapeutics, analysts believe Theriva Biologics is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.205, which suggesting that the stock is 79.546% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $14.1M, which are larger than Theriva Biologics quarterly revenues of --. Sage Therapeutics's net income of -$62.2M is lower than Theriva Biologics's net income of -$4.4M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 8.47x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -442.4% compared to Sage Therapeutics's net margin of --. Sage Therapeutics's return on equity of -64.19% beat Viking Therapeutics's return on equity of --.

Sage Therapeutics has a consensus price target of $8.21, signalling upside risk potential of 25.2%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 227.63%. Given that Viking Therapeutics has higher upside potential than Sage Therapeutics, analysts believe Viking Therapeutics is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.205, which suggesting that the stock is 79.546% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $14.1M, which are larger than Viking Therapeutics quarterly revenues of --. Sage Therapeutics's net income of -$62.2M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 8.47x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.